High Court Stays Mum On Teva MS Drug Patent Suit

Law360, New York (March 24, 2014, 7:18 PM EDT) -- The U.S. Supreme Court on Monday took no action for a second time in a patent case over Teva Pharmaceuticals USA Inc.'s lucrative multiple sclerosis drug Copaxone, as the clock ticks toward a possible May launch for planned generic versions of the drug.

Teva is appealing a July ruling by the Federal Circuit invalidating several patents covering the drug, which had worldwide sales of $4.3 billion in 2013, and clearing the way for generic versions. The high court was slated to discuss the case at its...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.